Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028 BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, t